相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)
M. Karoui et al.
ANNALS OF SURGERY (2020)
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study
Cynthia Reichling et al.
GUT (2020)
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study y
F. Pages et al.
ANNALS OF ONCOLOGY (2020)
?Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial?
Julien Taieb et al.
DIGESTIVE AND LIVER DISEASE (2020)
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Thierry Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
Julien Taieb et al.
CANCER TREATMENT REVIEWS (2019)
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
Matthew T. Seymour et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage Ill colon cancer (CC).
Frank A. Sinicrope et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer A phase III randomized study.
David Lau et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
Frank A. Sinicrope et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
J. Taieb et al.
ANNALS OF ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
J Taieb et al.
ANNALS OF ONCOLOGY (2019)
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
N. Tarazona et al.
ANNALS OF ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial
Jaafar Bennouna et al.
CLINICAL COLORECTAL CANCER (2019)
Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
Peng Gao et al.
BMC CANCER (2018)
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Claire Gallois et al.
CLINICAL CANCER RESEARCH (2018)
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)
Pierre Michel et al.
DIGESTIVE AND LIVER DISEASE (2018)
Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer
Megan C. Turner et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
60PDColon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
P Laurent-Puig et al.
ANNALS OF ONCOLOGY (2018)
Adjuvant FOLFOX plus /- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
J. Taieb et al.
ANNALS OF ONCOLOGY (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review
Gaowei Fan et al.
PLOS ONE (2017)
Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.
Laetitia Marisa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Pu Yan et al.
CLINICAL CANCER RESEARCH (2016)
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer
Alexandra Lapeyre-Prost et al.
CLINICAL COLORECTAL CANCER (2016)
PRODIGE 34-FFCD 1402-ADAGE Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial
Thomas Aparicio et al.
DIGESTIVE AND LIVER DISEASE (2016)
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Rachel S. Kerr et al.
LANCET ONCOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Piero Dalerba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
David Tougeron et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value
Gil Raga Mireia et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
D. G. Haller et al.
ANNALS OF ONCOLOGY (2015)
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer
Margaret M. Kozak et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway
B. Zhang et al.
BRITISH JOURNAL OF CANCER (2014)
Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Dmitri Mouradov et al.
CANCER RESEARCH (2014)
CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer
Stacey Shiovitz et al.
GASTROENTEROLOGY (2014)
Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data
Antonio F. Di Narzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
Julien Taieb et al.
LANCET ONCOLOGY (2014)
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
Nadine J. McCleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer
Enric Domingo et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
Jia-Xing Zhang et al.
LANCET ONCOLOGY (2013)
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer
H. J. Chang et al.
ANNALS OF ONCOLOGY (2012)
Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
Patrick G. Gavin et al.
CLINICAL CANCER RESEARCH (2012)
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
Trude H. Agesen et al.
GUT (2012)
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial
Steven R. Alberts et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont et al.
LANCET ONCOLOGY (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Aziz Zaanan et al.
CLINICAL CANCER RESEARCH (2011)
Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
Richard D. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis
Gaetan Des Guetz et al.
EUROPEAN JOURNAL OF CANCER (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase III randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M. Ychou et al.
ANNALS OF ONCOLOGY (2009)
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
Ivan Popov et al.
EUROPEAN JOURNAL OF CANCER (2008)
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer
Yuqiu Jiang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
Richard Gray et al.
LANCET (2007)
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Gene expression profiles and molecular markers to predict recurrence of dukes' B colon cancer
YX Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial
T André et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis
T Lecomte et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
DJ Sargent et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
